Skandinaviska Enskilda Banken AB publ Purchases 103,816 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Skandinaviska Enskilda Banken AB publ raised its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 35.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 396,279 shares of the biopharmaceutical company’s stock after buying an additional 103,816 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned 0.49% of Intra-Cellular Therapies worth $20,666,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Morgan Stanley boosted its position in shares of Intra-Cellular Therapies by 51.4% in the second quarter. Morgan Stanley now owns 663,263 shares of the biopharmaceutical company’s stock valued at $27,074,000 after acquiring an additional 225,202 shares during the period. SG Americas Securities LLC boosted its holdings in Intra-Cellular Therapies by 5.2% in the 3rd quarter. SG Americas Securities LLC now owns 21,483 shares of the biopharmaceutical company’s stock valued at $801,000 after purchasing an additional 1,065 shares during the period. Deutsche Bank AG grew its position in shares of Intra-Cellular Therapies by 30.6% during the 3rd quarter. Deutsche Bank AG now owns 199,120 shares of the biopharmaceutical company’s stock worth $7,424,000 after purchasing an additional 46,646 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Intra-Cellular Therapies by 54.2% during the third quarter. PNC Financial Services Group Inc. now owns 3,233 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 1,137 shares during the period. Finally, Russell Investments Group Ltd. raised its position in shares of Intra-Cellular Therapies by 46.3% in the third quarter. Russell Investments Group Ltd. now owns 398,489 shares of the biopharmaceutical company’s stock valued at $14,854,000 after buying an additional 126,168 shares in the last quarter. Hedge funds and other institutional investors own 73.40% of the company’s stock.

In related news, insider Suresh K. Durgam sold 3,860 shares of the firm’s stock in a transaction on Friday, March 4th. The stock was sold at an average price of $55.52, for a total transaction of $214,307.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suresh K. Durgam sold 4,177 shares of Intra-Cellular Therapies stock in a transaction dated Tuesday, February 22nd. The stock was sold at an average price of $55.29, for a total value of $230,946.33. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 280,157 shares of company stock worth $16,524,262. Company insiders own 13.20% of the company’s stock.

ITCI has been the subject of a number of recent analyst reports. Piper Sandler began coverage on Intra-Cellular Therapies in a research report on Friday, April 22nd. They set a “neutral” rating and a $59.00 target price for the company. The Goldman Sachs Group assumed coverage on shares of Intra-Cellular Therapies in a research report on Wednesday, February 16th. They set a “buy” rating and a $64.00 price objective for the company. SVB Leerink raised their target price on shares of Intra-Cellular Therapies from $65.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, April 21st. StockNews.com began coverage on shares of Intra-Cellular Therapies in a research report on Thursday, March 31st. They issued a “sell” rating for the company. Finally, Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Thursday, January 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $60.43.

Shares of Intra-Cellular Therapies stock opened at $43.00 on Tuesday. The company’s 50 day moving average price is $57.88 and its two-hundred day moving average price is $49.84. The firm has a market capitalization of $4.05 billion, a P/E ratio of -12.29 and a beta of 1.28. Intra-Cellular Therapies, Inc. has a fifty-two week low of $28.40 and a fifty-two week high of $66.00.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) last issued its quarterly earnings data on Tuesday, March 1st. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.05). The business had revenue of $25.67 million for the quarter, compared to analyst estimates of $24.93 million. Intra-Cellular Therapies had a negative return on equity of 54.89% and a negative net margin of 339.04%. Intra-Cellular Therapies’s quarterly revenue was up 106.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.76) EPS. Research analysts expect that Intra-Cellular Therapies, Inc. will post -3.16 earnings per share for the current year.

Intra-Cellular Therapies Profile (Get Rating)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults.

See Also